Related Experiment Video
Updated: Mar 14, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Variants of HSD11B2 gene in hypertensive disorders of pregnancy
Katarzyna Kosicka1, Anna Siemiątkowska1, Agnieszka Pękal1
1a Department of Physical Pharmacy and Pharmacokinetics , Poznan University of Medical Sciences , Poznań , Poland.
Introduction:
One of the hypotheses concerning the etiology of gestational hypertension (GH) and pre-eclampsia (PE) assumes that they develop as a result of placenta malfunctioning at the early stage of pregnancy. Placental dysfunction is also associated with the decreased activity of 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2), which in normal pregnancy protects the fetus from the excess of maternal cortisol.
Objective:
The aim of the study was to analyze the sequence of HSD11B2, a gene that encodes 11β-HSD2, searching for mutations and haplotypes associated with the increased risk of GH or PE. Those may serve as potential genetic markers of GH and PE.
Methods:
The study was performed in case-control structure and included pregnant women (in third trimester) diagnosed with: GH, PE or being normotensive (control group). The research comprised DNA sequencing of HSD11B2, followed by restriction analysis (PCR-RFLP). The linkage disequilibrium analysis and haplotype-based case-control analysis were performed.
Results:
Six sequence variations were observed. Four mutations were indicated in the coding region of HSD11B2 and the other two in 3'-UTR. Two SNPs: c.468C > A and c.534G > A were found to be in total disequilibrium.
Conclusions:
High variability in HSD11B2 sequence was indicated in the study population, but the relevance of observed SNPs to GH or PE development was not confirmed.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology
Hormonal Regulation
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic Lingo

